2
views
0
recommends
+1 Recommend
2 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Trayectoria tecnológica y productiva de la industria de vacunas humanas en México: perspectivas post Covid-19 Translated title: Technological and productive trajectory of the human vaccine industry in Mexico: post-Covid-19 perspectives

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          RESUMEN

          Las vacunas han transformado la salud a escala global. La perturbación causada por la pandemia de covid-19 reveló la fragilidad de los sistemas de salud en todo el mundo. Aquellos países con capacidades en el desarrollo y la fabricación de vacunas impulsaron el incremento del financiamiento para el desarrollo de posibles vacunas. México, otrora líder en producción de vacunas a escala mundial, pasó décadas de abandono y escasa capacidad de respuesta para atender a las necesidades que trajo consigo la pandemia. Este trabajo analiza la evolución de las capacidades de la industria productora de vacunas en México. La metodología hace una revisión crítica de la literatura con respecto a la evolución de la trayectoria productiva y tecnológica de la industria de las vacunas. Los hallazgos apuntan a que la industria de vacunas en México, derivado del deterioro de la inversión en el sector, la falta de flexibilidad organizacional de la empresa pública productora de vacunas y la ausencia de políticas públicas experimentó la pérdida de su capacidad para generar autonomía en la fabricación de vacunas, por lo que es imperioso revisar la necesidad de disponer de capacidades locales para la fabricación de vacunas como un área estratégica del desarrollo de la nación.

          ABSTRACT

          Vaccines have transformed health globally. The disruption caused by the Covid-19 pan-demic revealed the fragility of healthcare systems around the world. Those countries with capacities in the development and manufacture of vaccines promoted the increase in financing for the development of possible vaccines. In the case of Mexico, once the world leader in vaccine production, it exhibited decades of neglect and little response capacity to meet the needs brought about by the pandemic. This paper analyzes the evolution of the capacities of the vaccine production industry in Mexico. The methodology makes a critical review of the literature regarding the evolution of the productive and technological trajectory of the vaccine industry. The findings point to the fact that the vaccine industry in Mexico, derived from the deterioration of investment in the sector, the lack of organizational flexibility of the public company that produces vaccines, and the absence of public policies, caused the loss of the capacity to generate autonomy in the vaccine manufacturing, it is therefore imperative to review the need to have local capacities for vaccine manufacturing as a strategic area of development for the nation.

          Related collections

          Most cited references34

          • Record: found
          • Abstract: not found
          • Article: not found

          The fight to manufacture COVID vaccines in lower-income countries

          Amy Maxmen (2021)
            Bookmark
            • Record: found
            • Abstract: not found
            • Book: not found

            WHO coronavirus (covid-19) dash-board

              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              Impact of BRICS? investment in vaccine development on the global vaccine market

              Brazil, the Russian Federation, India, China and South Africa – the countries known as BRICS – have made considerable progress in vaccine production, regulation and development over the past 20 years. In 1993, all five countries were producing vaccines but the processes used were outdated and non-standardized, there was little relevant research and there was negligible international recognition of the products. By 2014, all five countries had strong initiatives for the development of vaccine technology and had greatly improved their national regulatory capacity. South Africa was then the only BRICS country that was not completely producing vaccines. South Africa is now in the process of re-establishing its own vaccine production and passing beyond the stage of simply importing, formulating and filling vaccine bulks. Changes in the public sector’s price per dose of selected vaccines, the global market share represented by products from specific manufacturers, and the attractiveness, for multinational companies, of partnership and investment opportunities in BRICS companies have all been analysed. The results indicate that the BRICS countries have had a major impact on vaccine price and availability, with much of that impact attributable to the output of Indian vaccine manufacturers. China is expected to have a greater impact soon, given the anticipated development of Chinese vaccine manufacturers in the near future. BRICS’ accomplishments in the field of vaccine development are expected to reshape the global vaccine market and accelerate access to vaccines in the developing world. The challenge is to turn these expectations into strategic actions and practical outcomes.
                Bookmark

                Author and article information

                Journal
                Rev Salud Publica (Bogota)
                Rev Salud Publica (Bogota)
                rsap
                Revista de Salud Pública
                Instituto de Salud Publica, Facultad de Medicina - Universidad Nacional de Colombia
                0124-0064
                2539-3596
                01 September 2023
                October 2023
                : 25
                : 5
                : 110791
                Affiliations
                [1 ] original MP: Lic. Economía. Ph. D. Economía y Gestión de la Innovación y Política Tecnológica. M. Sc. Economía y Gestión del Cambio Tecnológico. Centro de Investigaciones Económicas, Administrativas y Sociales (CIECAS), Instituto Politécnico Nacional (IPN). Ciudad de México, México. mpperez@ipn.mx normalizedInstituto Politécnico Nacional orgnameInstituto Politécnico Nacional Ciudad de México, Mexico mpperez@ 123456ipn.mx
                [2 ] original LC: MD. Ph.D.; M.Sc. Ciencias Biológicas. Centro de Investigaciones Económicas, Administrativas y Sociales (CIECAS), Instituto Politécnico Nacional (IPN). Ciudad de México, México. luis.castillo.chavez@gmail.com normalizedInstituto Politécnico Nacional orgnameInstituto Politécnico Nacional Ciudad de México, Mexico
                Article
                6
                10.15446/rsap.V25n5.110791
                11665046
                7abc55e8-099c-4a21-a1c9-1d59d740d6ac

                Este es un artículo publicado en acceso abierto bajo una licencia Creative Commons

                History
                : 25 August 2023
                : 22 August 2023
                : 30 August 2023
                Page count
                Figures: 2, Tables: 0, Equations: 0, References: 34, Pages: 7
                Categories
                Ensayo

                vacunas,méxico,industria farmacéutica,desarrollo tecnológico (fuente: decs, bireme),vaccines,mexico,drug industry,sustainable development (source: mesh, nlm)

                Comments

                Comment on this article

                scite_
                0
                0
                0
                0
                Smart Citations
                0
                0
                0
                0
                Citing PublicationsSupportingMentioningContrasting
                View Citations

                See how this article has been cited at scite.ai

                scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.

                Similar content135

                Most referenced authors104